Vincent Woo

University of Manitoba — Canada

Medicine · Health Sciences

51h-index22.7kcitations195works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(130), Diabetes Management and Research(98), Metabolism, Diabetes, and Cancer(54), Pancreatic function and diabetes(53), Hyperglycemia and glycemic control in critically ill and hospitalized patients(27)

Publications188 total

The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1–5
Diabetologia·2025· 3 citedOpen Access
830-P: No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes—ONWARDS 1–5
Diabetes·2024· 2 cited
Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study
Diabetes and Vascular Disease Research·2024· 4 citedOpen Access
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Obesity Reviews·2023· 24 citedOpen Access
EFFICACY AND SAFETY OF ONCE-WEEKLY INSULIN ICODEC VERSUS ONCE-DAILY INSULIN DEGLUDEC IN TYPE 1 DIABETES: ONWARDS 6
Canadian Journal of Diabetes·2023
IMPROVED A1C AND TIME IN RANGE WITH ONCE-WEEKLY INSULIN ICODEC VERSUS INSULIN GLARGINE U100 IN INSULIN-NAÏVE TYPE 2 DIABETES: ONWARDS 1
Canadian Journal of Diabetes·2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
The Lancet·2023· 97 citedOpen Access
EFFICACY AND SAFETY OF ONCE-WEEKLY INSULIN ICODEC VERSUS ONCE-DAILY INSULIN DEGLUDEC IN TYPE 1 DIABETES: ONWARDS 6
Canadian Journal of Cardiology·2023
IMPROVED A1C AND TIME IN RANGE WITH ONCE-WEEKLY INSULIN ICODEC VERSUS INSULIN GLARGINE U100 IN INSULIN-NAÏVE TYPE 2 DIABETES: ONWARDS 1
Canadian Journal of Cardiology·2023
134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review
Diabetes·2023
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
Diabetes Therapy·2023· 6 citedOpen Access
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the <scp>CANVAS</scp> programme and <scp>CREDENCE</scp>
Diabetes Obesity and Metabolism·2023· 2 citedOpen Access
Does “Traditionis custodes” Pass the Juridical Rationality Test? A Canonical-Theological Study by Réginald-Marie Rivoire (review)
˜The œJurist/˜The œjurist·2023
The Resistance Exercise in Already Active Diabetic Individuals (READI) Randomized Clinical Trial
The Journal of Clinical Endocrinology & Metabolism·2022· 3 citedOpen Access
Does diabetes affect the risk of involvement in a motor vehicle crash?
Journal of Transport & Health·2022· 1 cited
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
Canadian Journal of Cardiology·2022· 53 citedOpen Access
Table of Contents
Canadian Journal of Cardiology·2022Open Access
856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE
Diabetes·2022
Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
Indian Journal of Endocrinology and Metabolism·2022Open Access
Sacred Oils by Paul Turner
Antiphon·2022
page 1 of 10Next →

Frequent Co-authors

Lawrence A. Leiter(15), Alain Milot(11), Sheldon W. Tobe(11), Marcel Ruzicka(11), Ross D. Feldman(11), Ernesto L. Schiffrin(11), Robert A. Hegele(11), Robert J. Herman(11), Simon W. Rabkin(11), Tavis S. Campbell(11), Michael D. Hill(11), Gordon W. Moe(11), Luc Trudeau(11), Michel Vallée(10), Philip A. McFarlane(10), Ellen Burgess(10), Simon Bacon(10), Jonathan G. Howlett(10), Pavel Hamet(10), Richard Lewanczuk(10)